Sanofi-backed T-Therapeutics bags $59M in Series A to unlock potential of TCR therapeutics: #Jefferies23
LONDON — T-Therapeutics has raised £48 million ($59 million) in a Series A round supported by a Big Pharma investor to discover and develop new T cell receptor (TCR) therapeutics using its transgenic mouse technology.
The round was co-led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital with contributions from Sanofi Ventures and the University of Cambridge Venture Fund. T-Therapeutics will use the cash to advance drugs for cancer and inflammatory diseases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.